`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`______________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`______________
`
`
`
`APOTEX INC. and APOTEX CORP.,
`Petitioners,
`
`v.
`
`AUSPEX PHARMACEUTICALS, INC.,
`Patent Owner.
`_________________________________________________
`
`
`Case IPR2021-01507
`Patent 8,524,733
`
`_________________________________________________
`
`PATENT OWNER’S MANDATORY NOTICES
`
`
`
`
`
`
`
`Pursuant to 37 C.F.R. § 42.8, Patent Owner Auspex Pharmaceuticals, Inc.
`
`respectfully submits the following Mandatory Notices.
`
`I.
`
`REAL PARTIES IN INTEREST
`Auspex Pharmaceuticals, Inc. is the real party-in-interest. Out of an
`
`abundance of caution, the Patent Owner further identifies Teva Branded
`
`Pharmaceutical Products R&D, Inc. as a real party-in-interest for the purposes of
`
`providing notice in this IPR proceeding.
`
`II. RELATED MATTERS
`The Patent Owner identifies the following U.S. Patent applications and
`
`judicial matter that relate to U.S. Patent Application No. 12/562,261, which issued
`
`as U.S. Patent No. 8,524,733:
`
`• U.S. Patent Application No. 61/097,896, filed September 18, 2008, and
`
`now expired, is a provisional application from which U.S. Patent
`
`Application No. 12/562,261, which issued as U.S. Patent No.
`
`8,524,733, claims the benefit of priority.
`
`• U.S. Patent Application No. 13/934,960, filed July 3, 2013, and now
`
`abandoned, is a patent application that claims the benefit of priority
`
`1
`
`
`
`
`from U.S. Patent Application No. 12/562,261, which issued as U.S.
`
`Patent No. 8,524,733.
`
`• U.S. Patent No. 8,524,733 is the subject of a patent infringement
`
`lawsuit filed in the District of New Jersey in Civil Action No. 3:21-cv-
`
`13240, Teva Branded Pharmaceutical Products R&D, Inc. et al. v.
`
`Aurobindo Pharma Ltd. et al.
`
`The Patent Owner does not concede that any of the above-identified
`
`applications and judicial matter, aside from U.S. Patent No. 8,524,733, would affect,
`
`or be affected by, a decision in the present proceeding.
`
`III. COUNSEL
`The Patent Owner provides the following designation of counsel:
`
`Lead Counsel
`David I. Berl
`Williams & Connolly LLP
`725 12th St NW
`Washington, DC 20005
`Phone: 202-434-5491
`Fax: 202-434-5029
`dberl@wc.com
`USPTO Registration No: 72,751
`
`Backup Counsel
`Thomas S. Fletcher
`Williams & Connolly LLP
`725 12th St NW
`Washington, DC 20005
`Phone: 202-434-5497
`Fax: 202-434-5029
`tfletcher@wc.com
`USPTO Registration No: 72,383
`Backup Counsel
`Shaun P. Mahaffy
`Williams & Connolly LLP
`725 12th St NW
`Washington, DC 20005
`Phone: 202-434-5554
`Fax: 202-434-5029
`smahaffy@wc.com
`
`2
`
`
`
`
`USPTO Registration No. 75,534
`
`
`
`A Power of Attorney for the Patent Owner is being filed concurrently with
`
`these Mandatory Notices.
`
`IV. SERVICE INFORMATION
`The Patent Owner requests that all postal correspondence be addressed to lead
`
`counsel at the address shown above. The Patent Owner also consents to electronic
`
`service by email to TevaAustedo@wc.com.
`
`September 29, 2021
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`/s/ David I. Berl
`David I. Berl (Reg. No. 72,525)
`Thomas S. Fletcher (Reg. No. 72,383)
`Shaun P. Mahaffy (Reg. No. 75,534)
`Williams & Connolly LLP
`725 Twelfth Street NW
`Washington, DC 20005
`202-434-5000 (Telephone)
`202-434-5029 (Facsimile)
`
`
`
`
`
`3
`
`
`
`
`CERTIFICATE OF SERVICE
`Pursuant to 37 C.F.R. § 42.6(e), the undersigned hereby certifies that a true
`
`and correct copy of the foregoing was served on September 29, 2021, by delivering
`
`a copy via electronic mail on the following counsel of record for the Petitioner:
`
`
`
`
`
`
`
`Vishal Gupta
`STEPTOE & JOHNSON LLP
`1114 Avenue of the Americas
`New York, NY 10036
`212-506-3900 (Telephone)
`212-506-3950 (Facsimile)
`SJDeutetrabenazineIPR@steptoe.com
`
`
`
`
`
`
`
`
`
`
`September 29, 2021
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`/s/ David I. Berl
`David I. Berl (Reg. No. 72,525)
`
`4
`
`
`